EN
FR
ES
HI
VI
Invest in the production of
modern systems
of health diagnostics
Take part in developing the international business in the medical technology sector
up to 10 million products per year
project implementation time
up to 30%
annual growth in CGM sales
50%
of the company's profitability will be distributed in dividends
Contract manufacturing in China
— we will set up the first production line in the most cost-effective area on the planet
01
State-of-the-art production
We use advanced equipment, that has no counterparts around the world
02
In-house technology
We organize the production of goods developed by applying our in-house technology
03
Certification
We work with companies that supply well-known global brands
04
Logistics
We utilize the largest and cheapest logistics system to distribute goods worldwide
We have developed our own CGM system technology and obtained a number of patents. Now we have moved to the production stage. The demand for the systems worldwide is confirmed by the market research, and companies that have established themselves in this market are already valued at dozens of billions of dollars.
MORE ABOUT OUR PRODUCT
CGM (CONTINUOUS GLUCOSE MONITORING)
— is a continuous blood glucose monitoring system, a new generation of glucose meters.
01
Biosensor with a probe
Measures glucose levels in real time
02
Application
Mobile app to track minute-by-minute measurements
03
Alert
In case of an increase or decrease in glucose levels, the CGM has an alert function and transmits a signal to a mobile phone. The user is able to react promptly to the signal, preventing possible complications
1 out of 9
adults have impaired glucose tolerance (around 600 million people worldwide)
1 out of 2
cases of diabetes in adults remain undiagnosed (around 300 million people)
1.2 million
children and teenagers have type 1 diabetes
6.7 million
patients aged 20 to 79 die from diabetes-related causes. Almost half of them are in the age group of people under 60
The market for the industry and earnings prospects
The global industry of diabetes treatment is worth more than $ 75 billion and growing rapidly.
The volume of CGM offerings on the market cannot meet the demand and growing need worldwide.
Expanding access to modern treatments for diabetes is crucial to reducing costs and improving health outcomes.
$ 6.5 billion
Total profits of companies producing CGM devices
up to 30%
High markup on manufactured goods
up to 300%
The markup on the product ensures high profitability in large-scale production.
Investments accessible to anyone
Production investment shares are growing in value as production is ready to be launched and ramped up.
Purchase our investment shares at a favorable price!
up to 10 million products
First line production volume plan by 2028
up to 300%
High markup on manufactured goods
